Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11702960rdf:typepubmed:Citationlld:pubmed
pubmed-article:11702960lifeskim:mentionsumls-concept:C0278996lld:lifeskim
pubmed-article:11702960lifeskim:mentionsumls-concept:C0016640lld:lifeskim
pubmed-article:11702960lifeskim:mentionsumls-concept:C0205349lld:lifeskim
pubmed-article:11702960pubmed:issue10lld:pubmed
pubmed-article:11702960pubmed:dateCreated2001-11-12lld:pubmed
pubmed-article:11702960pubmed:abstractTextA conventional course of radiation for squamous cell carcinoma in the United States is generally 70 Gy in 7 weeks, with a once-daily dose of 1.8 to 2 Gy. This schedule has a modest success rate in curing head and neck cancer. The past several decades have seen numerous investigations into altering this schedule to optimize the results of radiation. Two approaches, founded on radiobiologic principles and clinical observations, have been tested with overlap between both concepts. Hyperfractionation is based on the ability to deliver radiotherapy in small fractions and increased total doses, while not adding to late toxicity. Accelerated fractionation is based on the observations that radiation injury causes accelerated tumor clonogen repopulation and that shortening the overall treatment time helps overcome this phenomenon. Both approaches have been shown to result in modest gains when tested in randomized trials, culminating with the completion of a Radiation Therapy Oncology Group trial (RTOG 9003). This randomized trial of more than 1,000 patients addressed various fractionation schedules proposed to improve results for head and neck cancer patients treated with radiation.lld:pubmed
pubmed-article:11702960pubmed:languageenglld:pubmed
pubmed-article:11702960pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11702960pubmed:citationSubsetIMlld:pubmed
pubmed-article:11702960pubmed:statusMEDLINElld:pubmed
pubmed-article:11702960pubmed:monthOctlld:pubmed
pubmed-article:11702960pubmed:issn0890-9091lld:pubmed
pubmed-article:11702960pubmed:authorpubmed-author:GardenA SASlld:pubmed
pubmed-article:11702960pubmed:issnTypePrintlld:pubmed
pubmed-article:11702960pubmed:volume15lld:pubmed
pubmed-article:11702960pubmed:ownerNLMlld:pubmed
pubmed-article:11702960pubmed:authorsCompleteYlld:pubmed
pubmed-article:11702960pubmed:pagination1326-32, 1334; discussion 1334, 1339-41lld:pubmed
pubmed-article:11702960pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:meshHeadingpubmed-meshheading:11702960...lld:pubmed
pubmed-article:11702960pubmed:year2001lld:pubmed
pubmed-article:11702960pubmed:articleTitleAltered fractionation for head and neck cancer.lld:pubmed
pubmed-article:11702960pubmed:affiliationDepartment of Radiation Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA.lld:pubmed
pubmed-article:11702960pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11702960pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11702960pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11702960lld:pubmed